7ACC-2
- Product Name
- 7ACC-2
- CAS No.
- 1472624-85-3
- Chemical Name
- 7ACC-2
- Synonyms
- 7ACC2;7ACC-2;7ACC 2;7ACC 2; 7ACC-2; 7ACC 2; 7ACC-2;7-[benzyl(methyl)amino]-2-oxochromene-3-carboxylic acid;7-[Benzyl(methyl)amino]-2-oxo-2H-chromene-3-carboxylic acid;2H-1-Benzopyran-3-carboxylic acid, 7-[methyl(phenylmethyl)amino]-2-oxo-;7ACC2,MPC,MCT1,7ACC-2,Monocarboxylate Transporter,Inhibitor,lactate,pyruvate,Mitochondrial Metabolism,radiosensitizes,antitumor,mitochondrial,inhibit
- CBNumber
- CB22729349
- Molecular Formula
- C18H15NO4
- Formula Weight
- 309.32
- MOL File
- 1472624-85-3.mol
7ACC-2 Property
- Boiling point:
- 548.9±50.0 °C(Predicted)
- Density
- 1.368±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- solubility
- insoluble in EtOH; insoluble in H2O; ≥47.5 mg/mL in DMSO
- form
- Powder
- pka
- -98.37±0.20(Predicted)
Safety
- HS Code
- 2932990090
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 23445
- Product name
- 7ACC2
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $32
- Updated
- 2024/03/01
- Product number
- 23445
- Product name
- 7ACC2
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $139
- Updated
- 2024/03/01
- Product number
- 23445
- Product name
- 7ACC2
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $243
- Updated
- 2024/03/01
- Product number
- 23445
- Product name
- 7ACC2
- Purity
- ≥98%
- Packaging
- 25mg
- Price
- $533
- Updated
- 2024/03/01
- Product number
- B4868
- Product name
- 7ACC2
- Packaging
- 10mg
- Price
- $660
- Updated
- 2021/12/16
7ACC-2 Chemical Properties,Usage,Production
Biological Activity
7acc2, a carboxycoumarin derivative, is a potent inhibitor of monocarboxylate transporter 1 (mct1), with an ic50 value of ~ 10 nm for lactate uptake in the human cervix carcinoma cell line siha. the family of mct is composed of 14 members, among which only four isoforms (i.e. mct1-4) have been documented to act as proton-linked transporters carrying short chain monocarboxylates such as lactate and pyruvate across cell membranes. in cancer cells, mct1 and mct4 are the most widely expressed, and mct1 shows a better affinity for l-lactate than mct4, enabling lactate entry into oxidative tumor cells. thus, mct1 blockade could serve as a potential therapeutic strategy to limit cancer progression. in addition, 7acc2 is also a potent inhibitor of mitochondrial pyruvate transport, which interferes with pyruvate import into mitochondria and ultimately prevents extracellular lactate uptake as efficiently as a mct1 inhibitor.1. draoui n, schicke o, fernandes a, et al. synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. bioorganic & medicinal chemistry, 2013, 21(22): 7107-7117.2. corbet c, bastien e, draoui n, et al. interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. nature communications, 2018, 9(1): 1208.
in vitro
7ACC-2 (compound 19; 72 hours) inhibits SiHa cells proliferation in lactate-containing medium with an EC50 of 0.22 μM. In SiHa cells, lactate uptake primarily depends on the high affinity MCT1 transporter.
It (compound 19) shows an excellent chemical stability in simulated gastric (SGF) and intestinal (SIF) fluids, a good apparent permeability coefficient (Papp) through Caco-2 monolayer and a high metabolic stability on mouse (MLM) and human liver microsomes ( HLM) as well as on human hepatocytes.
It is a potent inhibitor of mitochondrial pyruvate transport which consecutively blocks extracellular lactate uptake by promoting intracellular pyruvate accumulation.
p>
in vivo
7ACC-2 (3 mg/kg; intraperitoneal administration; daily; for 5 days or 10days) treatment significantly inhibits tumor growth in mice. It radiosensitizes tumor cells by reducing hypoxia in vivo.
The intraperitoneal administration of it (compound 19; 3 mg/kg) to mice leads to a C max of 1246 ng/ml (4 μM) in a very short time (T max =10 min) associated with a plasma half-life of 4.5 h.
| Animal Model: | 7-week-old female NMRI nude mice with radiotherapy administered |
| Dosage: | 3 mg/kg |
| Administration: | Intraperitoneal administration; daily; for 5 days or 10days |
| Result: | A significant increase in tumor growth delay was observed. |
target
| Target | Value |
| MCT1 () |